Petroleo Brasileiro SA Petrobras
PBR
Strategy
MSTR
Vale SA
VALE
KB Home
KBH
Apple
AAPL
US Stock MarketDetailed Quotes
AKBA Akebia Therapeutics
- 2.1300
- -0.0100-0.47%
Close Feb 14 16:00 ET
464.73MMarket Cap-9.68P/E (TTM)
2.1700High2.1100Low1.31MVolume2.1300Open2.1400Pre Close2.79MTurnover0.66%Turnover RatioLossP/E (Static)218.18MShares2.480052wk High-9.22P/B421.63MFloat Cap0.800052wk Low--Dividend TTM197.95MShs Float31.0000Historical High--Div YieldTTM2.80%Amplitude0.2410Historical Low2.1330Avg Price1Lot Size
About Akebia Therapeutics Company
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.
Company Profile
SymbolAKBA
Company NameAkebia Therapeutics
Listing DateMar 20, 2014
Issue Price17.00
Founded2007
CEOMr. John P. Butler
MarketNASDAQ
Employees167
Fiscal Year Ends12-31
Address245 First Street,Suite 1400
CityCambridge
ProvinceMassachusetts
CountryUnited States of America
Zip Code02142
Phone1-617-871-2098
Websitehttp://www.akebia.com
Company Executives
- Name
- Position
- Salary
- John P. Butler
- Director, President and Chief Executive Officer
- 2.78M
- Dr. Steven Keith Burke, M.D.
- Senior Vice President, Research and Development and Chief Medical Officer
- 1.21M
- Nicholas Grund
- Senior Vice President and Chief Commercial Officer
- --
- Richard C. Malabre
- Chief Accounting Officer
- --
- Erik John Ostrowski
- Senior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer
- --
- Adrian Adams
- Chairman of the Board
- 171.63K
- Dr. Steven C. Gilman, PhD
- Independent Director
- 139.87K
- Dr. Myles Wolf, M.D.
- Independent Director
- 144.43K
- Cynthia Smith
- Independent Director
- 151.50K
- LeAnne M. Zumwalt
- Independent Director
- 143.31K
- Ronald E. Frieson
- Independent Director
- 147.97K
- Michael W. Rogers
- Independent Director
- 145.79K
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.